Global Uterine Leiomyoma (Uterine Fibroids) - API Manufacturers, Marketed and Phase III Drugs Landscape - 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018′ report provides comprehensive insights about marketed and Phase III products for Uterine Leiomyoma (Uterine Fibroids) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Uterine Leiomyoma (Uterine Fibroids)
Coverage of API manufacturers for Uterine Leiomyoma (Uterine Fibroids) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
Emerging Phase III products for Uterine Leiomyoma (Uterine Fibroids)
This report provides a comprehensive understanding of the emerging Phase III therapies for Uterine Leiomyoma (Uterine Fibroids) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
Key Topics Covered:
1. Report Introduction
2. Uterine Leiomyoma (Uterine Fibroids): OverviewRisk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed TherapiesProduct Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities United States Europe Historical Global Sales Forecasted Global Sales
5. Emerging Therapies (Phase III)Product Description Research and Development Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jf6jnx/global_uterine?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005255/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Women’s Health
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 04:25 AM/DISC: 12/19/2018 04:26 AM